{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:21:12Z","timestamp":1791307272802,"version":"4.3.1"},"reference-count":96,"publisher":"SAGE Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HAB"],"published-print":{"date-parts":[[2020,12,9]]},"abstract":"<jats:p>Monoclonal antibodies and vaccines have widely been studied for the immunotherapy of cancer, though their large size appears to limit their functionality in solid tumors, in large part due to unique properties of tumor microenvironment. Smaller formats of antibodies have been developed to throw such restrictions. These small format antibodies include antigen binding fragments, single-chain variable fragments, single variable domain of camelid antibody (so-called nanobody (Nb) or VHH). Since their serendipitous discovery, nanobodies have been studies at length in the fields of research, diagnostics and therapy. These antigen binding fragments, originating from camelid heavy-chain antibodies, possess unusual hallmarks in terms of (small) size, stability, solubility and specificity, hence allowing cost-effective production and sometimes out performing monoclonal antibodies. In addition, these small camelid heavy-chain antibodies are highly adaptable tools for cancer research as they enable specific modulation of targets, enzymatic and non-enzymatic proteins alike. Molecular imaging studies benefit from the rapid, homogeneous tumor accumulation of nanobodies and their fast blood clearance, permitting previously unattainable fast tumor visualization. Moreover, they are endowed with considerable therapeutic potential as inhibitors of receptor-ligand pairs and deliverers of drugs or drug-loaded nanoparticles towards tumors. In this review, we shed light on the current status of nanobodies in diagnosis and imaging of tumor and exploiting nanobodies revert immunosuppressive events, modulation of immune checkpoints, and as deliverers of drugs for targeted tumor therapy.<\/jats:p>","DOI":"10.3233\/hab-200425","type":"journal-article","created":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T11:53:01Z","timestamp":1597751581000},"page":"259-272","source":"Crossref","is-referenced-by-count":13,"title":["Nanobodies as versatile tools: A focus on targeted tumor therapy, tumor imaging and diagnostics"],"prefix":"10.1177","volume":"28","author":[{"given":"Raid Saleem","family":"Al-Baradie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/HAB-200425_ref1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10529-013-1340-1","article-title":"A novel VHH nanobody against the active site (the CA domain) of tumor-associated, carbonic anhydrase isoform IX and its usefulness for cancer diagnosis","volume":"36","author":"Araste","year":"2014","journal-title":"Biotechnology Letters"},{"key":"10.3233\/HAB-200425_ref2","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.3389\/fimmu.2017.01589","article-title":"Camelid single-domain antibodies: Historical perspective and future outlook","volume":"8","author":"Arbabi-Ghahroudi","year":"2017","journal-title":"Frontiers in Immunology"},{"key":"10.3233\/HAB-200425_ref3","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ejcb.2016.07.004","article-title":"The hallmarks of CAFs in cancer invasion","volume":"95","author":"Attieh","year":"2016","journal-title":"European Journal of Cell Biology"},{"key":"10.3233\/HAB-200425_ref5","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1158\/2326-6066.CIR-15-0059","article-title":"Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells","volume":"3","author":"Boyerinas","year":"2015","journal-title":"Cancer Immunology Research"},{"key":"10.3233\/HAB-200425_ref6","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3390\/cancers11060872","article-title":"Evaluating a single domain antibody targeting human PD-L1 as a nuclear imaging and therapeutic agent","volume":"11","author":"Broos","year":"2019","journal-title":"Cancers"},{"key":"10.3233\/HAB-200425_ref7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2174\/1874471010801010037","article-title":"99mTc-labeled nanobodies: A new type of targeted probes for imaging antigen expression","volume":"1","author":"Caveliers","year":"2008","journal-title":"Current Radiopharmaceuticals"},{"key":"10.3233\/HAB-200425_ref8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/antib8010013","article-title":"Nanobody engineering: Toward next generation immunotherapies and immunoimaging of cancer","volume":"8","author":"Chanier","year":"2019","journal-title":"Antibodies"},{"key":"10.3233\/HAB-200425_ref9","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.talanta.2015.10.027","article-title":"Nanobody medicated immunoassay for ultrasensitive detection of cancer biomarker alpha-fetoprotein","volume":"147","author":"Chen","year":"2016","journal-title":"Talanta"},{"key":"10.3233\/HAB-200425_ref10","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1080\/21645515.2015.1056953","article-title":"Tim-3 and Tim-4 as the potential targets for antitumor therapy","volume":"11","author":"Cheng","year":"2015","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"10.3233\/HAB-200425_ref11","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.it.2017.06.004","article-title":"The ambiguous role of \u03b3\u2062\u03b4 T lymphocytes in antitumor immunity","volume":"38","author":"Chitadze","year":"2017","journal-title":"Trends in Immunology"},{"key":"10.3233\/HAB-200425_ref12","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1158\/0008-5472.CAN-03-3935","article-title":"Efficient cancer therapy with a nanobody-based conjugate","volume":"64","author":"Cortez-Retamozo","year":"2004","journal-title":"Cancer Research"},{"key":"10.3233\/HAB-200425_ref13","doi-asserted-by":"crossref","first-page":"6616","DOI":"10.1158\/1078-0432.CCR-17-0310","article-title":"131I-labeled anti-HER2 camelid sdAb as a theranostic tool in cancer treatment","volume":"23","author":"D\u2019Huyvetter","year":"2017","journal-title":"Clinical Cancer Research"},{"key":"10.3233\/HAB-200425_ref14","doi-asserted-by":"crossref","first-page":"708","DOI":"10.7150\/thno.8156","article-title":"Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody","volume":"4","author":"D\u2019Huyvetter","year":"2014","journal-title":"Theranostics"},{"key":"10.3233\/HAB-200425_ref15","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3390\/ijms19020403","article-title":"Nanobody based dual specific CARs","volume":"19","author":"De Munter","year":"2018","journal-title":"International Journal of Molecular Sciences"},{"key":"10.3233\/HAB-200425_ref16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/antib8010012","article-title":"Targeted nanobody-based molecular tracers for nuclear imaging and image-guided surgery","volume":"8","author":"Debie","year":"2019","journal-title":"Antibodies"},{"key":"10.3233\/HAB-200425_ref17","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1158\/2159-8290.CD-16-0241","article-title":"Cellular senescence promotes adverse effects of chemotherapy and cancer relapse","volume":"7","author":"Demaria","year":"2017","journal-title":"Cancer Discovery"},{"key":"10.3233\/HAB-200425_ref19","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nature18930","article-title":"Synchronized cycles of bacterial lysis for in vivo delivery","volume":"536","author":"Din","year":"2016","journal-title":"Nature"},{"key":"10.3233\/HAB-200425_ref20","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/eji.201646875","article-title":"Immune checkpoints and their inhibition in cancer and infectious diseases","volume":"47","author":"Dyck","year":"2017","journal-title":"European Journal of Immunology"},{"key":"10.3233\/HAB-200425_ref21","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nature19364","article-title":"Ionic immune suppression within the tumour microenvironment limits T-cell effector function","volume":"537","author":"Eil","year":"2016","journal-title":"Nature"},{"key":"10.3233\/HAB-200425_ref22","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1039\/c2mb25063b","article-title":"Single-domain antibodies: A versatile and rich source of binders for breast cancer diagnostic approaches","volume":"8","author":"Even-Desrumeaux","year":"2012","journal-title":"Molecular BioSystems"},{"key":"10.3233\/HAB-200425_ref23","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1002\/anie.201509432","article-title":"Structurally defined \u03b1MHC-II nanobody-drug conjugates: A therapeutic and imaging system for B-cell lymphoma","volume":"55","author":"Fang","year":"2016","journal-title":"Angewandte Chemie International Edition"},{"key":"10.3233\/HAB-200425_ref24","doi-asserted-by":"crossref","first-page":"788","DOI":"10.2967\/jnumed.107.048538","article-title":"Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT\/micro-CT","volume":"49","author":"Gainkam","year":"2008","journal-title":"Journal of Nuclear Medicine"},{"key":"10.3233\/HAB-200425_ref25","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1007\/s11307-010-0428-4","article-title":"Correlation between epidermal growth factor receptor-specific nanobody uptake and tumor burden: A tool for noninvasive monitoring of tumor response to therapy","volume":"13","author":"Gainkam","year":"2011","journal-title":"Molecular Imaging and Biology"},{"key":"10.3233\/HAB-200425_ref26","doi-asserted-by":"crossref","unstructured":"C.R. Gurbatri, I. Lia, R. Vincent, C. Coker, S. Castro, P.M. Treuting, T.E. Hinchliffe, N. Arpaia and T. Danino, Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies, Science Translational Medicine 12 (2020).","DOI":"10.1126\/scitranslmed.aax0876"},{"key":"10.3233\/HAB-200425_ref27","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/363446a0","article-title":"Naturally occurring antibodies devoid of light chains","volume":"363","author":"Hamers-Casterman","year":"1993","journal-title":"Nature"},{"key":"10.3233\/HAB-200425_ref28","doi-asserted-by":"crossref","first-page":"e1377874","DOI":"10.1080\/2162402X.2017.1377874","article-title":"ATTACK, a novel bispecific T-cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy","volume":"7","author":"Harwood","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.3233\/HAB-200425_ref29","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jconrel.2011.12.007","article-title":"Nanobody-coupled microbubbles as novel molecular tracer","volume":"158","author":"Hernot","year":"2012","journal-title":"Journal of Controlled Release"},{"key":"10.3233\/HAB-200425_ref30","doi-asserted-by":"crossref","unstructured":"P. Holliger, T. Prospero and G. Winter, \u201cDiabodies\u201d: Small bivalent and bispecific antibody fragments, Proceedings of the National Academy of Sciences 90 (1993), 6444\u20136448.","DOI":"10.1073\/pnas.90.14.6444"},{"key":"10.3233\/HAB-200425_ref31","first-page":"1201","article-title":"Preparation and characterization of a novel nanobody against T-cell immunoglobulin and mucin-3 (TIM-3)","volume":"19","author":"Homayouni","year":"2016","journal-title":"Iranian Journal of Basic Medical Sciences"},{"key":"10.3233\/HAB-200425_ref32","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.3389\/fimmu.2017.01442","article-title":"Nanobody-based delivery systems for diagnosis and targeted tumor therapy","volume":"8","author":"Hu","year":"2017","journal-title":"Frontiers in Immunology"},{"key":"10.3233\/HAB-200425_ref33","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11307-008-0133-8","article-title":"SPECT imaging with 99m Tc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression","volume":"10","author":"Huang","year":"2008","journal-title":"Molecular Imaging and Biology"},{"key":"10.3233\/HAB-200425_ref34","doi-asserted-by":"crossref","first-page":"e1249561","DOI":"10.1080\/2162402X.2016.1249561","article-title":"Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer","volume":"6","author":"Huang","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.3233\/HAB-200425_ref35","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/icb.2014.93","article-title":"Bispecific T-cell engagers for cancer immunotherapy","volume":"93","author":"Huehls","year":"2015","journal-title":"Immunology and Cell Biology"},{"key":"10.3233\/HAB-200425_ref36","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/03007995.2017.1421528","article-title":"An overview on the current status of cancer nanomedicines","volume":"34","author":"Jabir","year":"2018","journal-title":"Current Medical Research and Opinion"},{"key":"10.3233\/HAB-200425_ref37","doi-asserted-by":"crossref","unstructured":"N. Jailkhani, J.R. Ingram, M. Rashidian, S. Rickelt, C. Tian, H. Mak, Z. Jiang, H.L. Ploegh and R.O. Hynes, Noninvasive imaging of tumor progression, metastasis, and fibrosis using a nanobody targeting the extracellular matrix, Proceedings of the National Academy of Sciences 116 (2019), 14181\u201314190.","DOI":"10.1073\/pnas.1817442116"},{"key":"10.3233\/HAB-200425_ref38","first-page":"814s","article-title":"Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors","volume":"50","author":"Jain","year":"1990","journal-title":"Cancer Research"},{"key":"10.3233\/HAB-200425_ref39","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.yexcr.2012.03.004","article-title":"Targeting high affinity and epitope-distinct oligoclonal nanobodies to HER2 over-expressing tumor cells","volume":"318","author":"Jamnani","year":"2012","journal-title":"Experimental Cell Research"},{"key":"10.3233\/HAB-200425_ref40","first-page":"1","article-title":"The therapeutic potential of nanobodies","author":"Jov\u010devska","year":"2019","journal-title":"BioDrugs"},{"key":"10.3233\/HAB-200425_ref41","doi-asserted-by":"crossref","unstructured":"I. Jov\u010devska, N. Zupanec, N. Ko\u010devar, D. Cesselli, N. Podergajs, C.L. Stokin, M.P. Myers, S. Muyldermans, G.H. Ghassabeh and H. Motaln, TRIM28 and \u03b2-actin identified via nanobody-based reverse proteomics approach as possible human glioblastoma biomarkers, PloS One 9 (2014).","DOI":"10.1371\/journal.pone.0113688"},{"key":"10.3233\/HAB-200425_ref42","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2967\/jnumed.115.162024","article-title":"Phase I study of 68Ga-HER2-nanobody for PET\/CT assessment of HER2 expression in breast carcinoma","volume":"57","author":"Keyaerts","year":"2016","journal-title":"Journal of Nuclear Medicine"},{"key":"10.3233\/HAB-200425_ref43","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1080\/08830185.2018.1526932","article-title":"Single-domain antibodies or nanobodies: A class of next-generation antibodies","volume":"37","author":"Khodabakhsh","year":"2018","journal-title":"International Reviews of Immunology"},{"key":"10.3233\/HAB-200425_ref44","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1007\/s00259-013-2471-2","article-title":"Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery","volume":"40","author":"Kijanka","year":"2013","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"10.3233\/HAB-200425_ref45","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.ddtec.2010.03.002","article-title":"Nanobodies-from llamas to therapeutic proteins","volume":"7","author":"Kolkman","year":"2010","journal-title":"Drug Discovery Today: Technologies"},{"key":"10.3233\/HAB-200425_ref46","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/sj.bjc.6604483","article-title":"Tumour-targeted nanomedicines: Principles and practice","volume":"99","author":"Lammers","year":"2008","journal-title":"British Journal of Cancer"},{"key":"10.3233\/HAB-200425_ref47","doi-asserted-by":"crossref","first-page":"7772","DOI":"10.7150\/thno.34941","article-title":"Theranostics in immuno-oncology using nanobody derivatives","volume":"9","author":"Lecocq","year":"2019","journal-title":"Theranostics"},{"key":"10.3233\/HAB-200425_ref48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms13354","article-title":"Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy","volume":"7","author":"Lee","year":"2016","journal-title":"Nature Communications"},{"key":"10.3233\/HAB-200425_ref49","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.addr.2011.04.006","article-title":"Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor","volume":"64","author":"Li","year":"2012","journal-title":"Advanced Drug Delivery Reviews"},{"key":"10.3233\/HAB-200425_ref50","doi-asserted-by":"crossref","unstructured":"Y. Li, C. Zhou, J. Li, J. Liu, L. Lin, L. Li, D. Cao, Q. Li and Z. Wang, Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells, PloS one 13 (2018).","DOI":"10.1371\/journal.pone.0191024"},{"key":"10.3233\/HAB-200425_ref52","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0021-9258(17)42334-9","article-title":"Construction, expression, and activity of a bivalent bispecific single-chain antibody","volume":"269","author":"Mallender","year":"1994","journal-title":"Journal of Biological Chemistry"},{"key":"10.3233\/HAB-200425_ref53","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1021\/bc500111t","article-title":"Site-specific labeling of cysteine-tagged camelid single-domain antibody-fragments for use in molecular imaging","volume":"25","author":"Massa","year":"2014","journal-title":"Bioconjugate Chemistry"},{"key":"10.3233\/HAB-200425_ref54","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2174\/1573395515666190611122818","article-title":"Double-crosser of the immune system: Macrophages in tumor progression and metastasis","volume":"15","author":"Mir","year":"2019","journal-title":"Current Immunology Reviews"},{"key":"10.3233\/HAB-200425_ref55","first-page":"1","article-title":"Nanobodies: The \u201cmagic bullets\u201d in therapeutics, drug delivery and diagnostics","author":"Mir","year":"2019","journal-title":"Human Antibodies"},{"key":"10.3233\/HAB-200425_ref56","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00262-018-2181-5","article-title":"Bispecific light T-cell engagers for gene-based immunotherapy of epidermal growth factor receptor (EGFR)-positive malignancies","volume":"67","author":"M\u00f8lgaard","year":"2018","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10.3233\/HAB-200425_ref57","doi-asserted-by":"crossref","first-page":"104790","DOI":"10.1016\/j.phrs.2020.104790","article-title":"Nanobody-based therapeutics against colorectal cancer: Precision therapies based on the personal mutanome profile and tumor neoantigens","author":"Moradi","year":"2020","journal-title":"Pharmacological Research"},{"key":"10.3233\/HAB-200425_ref58","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1158\/0008-5472.CAN-11-2994","article-title":"Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages","volume":"72","author":"Movahedi","year":"2012","journal-title":"Cancer Research"},{"key":"10.3233\/HAB-200425_ref59","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.tips.2014.03.003","article-title":"GPCR-targeting nanobodies: Attractive research tools, diagnostics, and therapeutics","volume":"35","author":"Muji\u0107-Deli\u0107","year":"2014","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.3233\/HAB-200425_ref60","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","article-title":"Nanobodies: Natural single-domain antibodies","volume":"82","author":"Muyldermans","year":"2013","journal-title":"Annual Review of Biochemistry"},{"key":"10.3233\/HAB-200425_ref61","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1093\/protein\/7.9.1129","article-title":"Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains","volume":"7","author":"Muyldermans","year":"1994","journal-title":"Protein Engineering, Design Selection"},{"key":"10.3233\/HAB-200425_ref62","first-page":"3305","article-title":"Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: In vitro analysis of tumor-stromal interactions","volume":"57","author":"Nakamura","year":"1997","journal-title":"Cancer Research"},{"key":"10.3233\/HAB-200425_ref64","doi-asserted-by":"crossref","first-page":"7290","DOI":"10.2310\/7290.2011.00025","article-title":"Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody","volume":"11","author":"Oliveira","year":"2012","journal-title":"Molecular Imaging"},{"key":"10.3233\/HAB-200425_ref65","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00262-015-1671-y","article-title":"CEA\/CD3-bispecific T-cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1","volume":"64","author":"Osada","year":"2015","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10.3233\/HAB-200425_ref66","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.talanta.2014.06.069","article-title":"Nanoimmunoassay onto a screen printed electrode for HER2 breast cancer biomarker determination","volume":"130","author":"Patris","year":"2014","journal-title":"Talanta"},{"key":"10.3233\/HAB-200425_ref67","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1423-0127-17-21","article-title":"Bacteria in cancer therapy: A novel experimental strategy","volume":"17","author":"Patyar","year":"2010","journal-title":"Journal of Biomedical Science"},{"key":"10.3233\/HAB-200425_ref68","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/cbdd.12871","article-title":"99mTc-anti-epidermal growth factor receptor nanobody for tumor imaging","volume":"89","author":"Piramoon","year":"2017","journal-title":"Chemical Biology & Drug Design"},{"key":"10.3233\/HAB-200425_ref69","first-page":"5","article-title":"Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia","volume":"5","author":"Portell","year":"2013","journal-title":"Clinical Pharmacology: Advances and Applications"},{"key":"10.3233\/HAB-200425_ref70","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2967\/jnumed.113.127100","article-title":"Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling","volume":"55","author":"Pruszynski","year":"2014","journal-title":"Journal of Nuclear Medicine"},{"key":"10.3233\/HAB-200425_ref71","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.nucmedbio.2012.08.008","article-title":"Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody","volume":"40","author":"Pruszynski","year":"2013","journal-title":"Nuclear Medicine and Biology"},{"key":"10.3233\/HAB-200425_ref72","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.2174\/1381612822666160923114417","article-title":"Identification of useful nanobodies by phage display of immune single domain libraries derived from camelid heavy chain antibodies","volume":"22","author":"Romao","year":"2016","journal-title":"Current Pharmaceutical Design"},{"key":"10.3233\/HAB-200425_ref73","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3389\/fmicb.2017.00495","article-title":"Antibody engineering for pursuing a healthier future","volume":"8","author":"Saeed","year":"2017","journal-title":"Frontiers in Microbiology"},{"key":"10.3233\/HAB-200425_ref76","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0169-409X(01)00206-X","article-title":"Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates","volume":"53","author":"Senter","year":"2001","journal-title":"Advanced Drug Delivery Reviews"},{"key":"10.3233\/HAB-200425_ref77","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1007\/s12033-012-9601-0","article-title":"Development of oligoclonal nanobodies for targeting the tumor-associated glycoprotein 72 antigen","volume":"54","author":"Sharifzadeh","year":"2013","journal-title":"Molecular Biotechnology"},{"key":"10.3233\/HAB-200425_ref78","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: Progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nature Reviews Cancer"},{"key":"10.3233\/HAB-200425_ref79","doi-asserted-by":"crossref","unstructured":"D.D. Sloan, C.-Y.K. Lam, A. Irrinki, L. Liu, A. Tsai, C.S. Pace, J. Kaur, J.P. Murry, M. Balakrishnan and P.A. Moore, Targeting HIV reservoir in infected CD4 T-cells by dual-affinity re-targeting molecules (DARTs) that bind HIV envelope and recruit cytotoxic T-cells, PLoS Pathogens 11 (2015).","DOI":"10.1371\/journal.ppat.1005233"},{"key":"10.3233\/HAB-200425_ref80","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.drudis.2016.04.003","article-title":"Nanobodies as therapeutics: Big opportunities for small antibodies","volume":"21","author":"Steeland","year":"2016","journal-title":"Drug Discovery Today"},{"key":"10.3233\/HAB-200425_ref81","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.3390\/ijms19071984","article-title":"PD-L1 nanobody competitively inhibits the formation of the PD-1\/PD-L1 complex: Comparative molecular dynamics simulations","volume":"19","author":"Sun","year":"2018","journal-title":"International Journal of Molecular Sciences"},{"key":"10.3233\/HAB-200425_ref82","first-page":"1074","article-title":"Nanomedicine for treatment of cancer","volume":"105","author":"Sun","year":"2016","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.3233\/HAB-200425_ref83","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/cmmi.408","article-title":"Localization, mechanism and reduction of renal retention of technetium-99m labeled epidermal growth factor receptor-specific nanobody in mice","volume":"6","author":"Tchouate Gainkam","year":"2011","journal-title":"Contrast Media & Molecular Imaging"},{"key":"10.3233\/HAB-200425_ref84","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1001\/jama.2017.14155","article-title":"Targeting immune checkpoints in cancer therapy","volume":"318","author":"Topalian","year":"2017","journal-title":"Jama"},{"key":"10.3233\/HAB-200425_ref85","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ebiom.2016.04.028","article-title":"Nanobodies as versatile tools to understand, diagnose, visualize and treat cancer","volume":"8","author":"Van Audenhove","year":"2016","journal-title":"EBioMedicine"},{"key":"10.3233\/HAB-200425_ref86","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1021\/nn1023363","article-title":"Specific cell targeting with nanobody conjugated branched gold nanoparticles for photothermal therapy","volume":"5","author":"Van de Broek","year":"2011","journal-title":"ACS Nano"},{"key":"10.3233\/HAB-200425_ref87","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jconrel.2016.03.014","article-title":"EGFR targeted nanobody-photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer","volume":"229","author":"Van Driel","year":"2016","journal-title":"Journal of Controlled Release"},{"key":"10.3233\/HAB-200425_ref88","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1096\/fj.10-180331","article-title":"Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer","volume":"25","author":"Vaneycken","year":"2011","journal-title":"The FASEB Journal"},{"key":"10.3233\/HAB-200425_ref89","doi-asserted-by":"crossref","first-page":"6689","DOI":"10.1002\/adma.201400703","article-title":"Designing multi-branched gold nanoechinus for nir light activated dual modal photodynamic and photothermal therapy in the second biological window","volume":"26","author":"Vijayaraghavan","year":"2014","journal-title":"Advanced Materials"},{"key":"10.3233\/HAB-200425_ref90","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/0168-9525(93)90209-Z","article-title":"The multistep nature of cancer","volume":"9","author":"Vogelstein","year":"1993","journal-title":"Trends in Genetics"},{"key":"10.3233\/HAB-200425_ref91","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00259-010-1700-1","article-title":"Facile labelling of an anti-epidermal growth factor receptor Nanobody with 68 Ga via a novel bifunctional desferal chelate for immuno-PET","volume":"38","author":"Vosjan","year":"2011","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"10.3233\/HAB-200425_ref92","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1158\/1535-7163.MCT-11-0891","article-title":"Nanobodies targeting the hepatocyte growth factor: Potential new drugs for molecular cancer therapy","volume":"11","author":"Vosjan","year":"2012","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.3233\/HAB-200425_ref93","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1586\/14737140.7.6.833","article-title":"Nanotechnology for targeted cancer therapy","volume":"7","author":"Wang","year":"2007","journal-title":"Expert Review of Anticancer Therapy"},{"key":"10.3233\/HAB-200425_ref94","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3390\/antib8030043","article-title":"Design and production of bispecific antibodies","volume":"8","author":"Wang","year":"2019","journal-title":"Antibodies"},{"key":"10.3233\/HAB-200425_ref95","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00430-009-0116-7","article-title":"Single domain antibodies: Promising experimental and therapeutic tools in infection and immunity","volume":"198","author":"Wesolowski","year":"2009","journal-title":"Medical Microbiology and Immunology"},{"key":"10.3233\/HAB-200425_ref96","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/S1359-6446(05)03554-3","article-title":"BiTEs: Bispecific antibody constructs with unique anti-tumor activity","volume":"10","author":"Wolf","year":"2005","journal-title":"Drug Discovery Today"},{"key":"10.3233\/HAB-200425_ref97","doi-asserted-by":"crossref","first-page":"776","DOI":"10.2967\/jnumed.112.111021","article-title":"Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer","volume":"54","author":"Xavier","year":"2013","journal-title":"Journal of Nuclear Medicine"},{"key":"10.3233\/HAB-200425_ref98","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.tranon.2017.07.003","article-title":"BiHC, a T-cell\u2013engaging bispecific recombinant antibody, has potent cytotoxic activity against Her2 tumor cells","volume":"10","author":"Xing","year":"2017","journal-title":"Translational Oncology"},{"key":"10.3233\/HAB-200425_ref99","doi-asserted-by":"crossref","first-page":"169","DOI":"10.5301\/jbm.5000063","article-title":"Production of nanobodies against prostate-specific membrane antigen (PSMA) recognizing LnCaP cells","volume":"29","author":"Zare","year":"2014","journal-title":"The International Journal of Biological Markers"},{"key":"10.3233\/HAB-200425_ref100","doi-asserted-by":"crossref","unstructured":"W. Zhan, W. Gedroyc and X.Y. Xu, The effect of tumour size on drug transport and uptake in 3-D tumour models reconstructed from magnetic resonance images, PloS One 12 (2017).","DOI":"10.1371\/journal.pone.0172276"},{"key":"10.3233\/HAB-200425_ref101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/celldisc.2017.4","article-title":"Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade","volume":"3","author":"Zhang","year":"2017","journal-title":"Cell Discovery"},{"key":"10.3233\/HAB-200425_ref102","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.carbpol.2016.08.072","article-title":"Cisplatin-crosslinked glutathione-sensitive micelles loaded with doxorubicin for combination and targeted therapy of tumors","volume":"155","author":"Zhang","year":"2017","journal-title":"Carbohydrate Polymers"}],"container-title":["Human Antibodies"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/HAB-200425","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:22:22Z","timestamp":1777447342000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/HAB-200425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,9]]},"references-count":96,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3233\/hab-200425","relation":{},"ISSN":["1875-869X","1093-2607"],"issn-type":[{"value":"1875-869X","type":"electronic"},{"value":"1093-2607","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,9]]}}}